BENDHEIM JACK 4

4 · PHIBRO ANIMAL HEALTH CORP · Filed Mar 16, 2026

AI-generated summary of this filing

Updated Mar 16, 2026

PHIBRO (PAHC) 10% Owner Jack Bendheim Sells 5,280 Shares

What Happened

Jack Bendheim (10% owner, director and officer) converted Class B shares into Class A on March 12, 2026 (100,000 shares converted one‑for‑one, no cash) and sold 5,280 Class A shares in the open market on March 13, 2026 for roughly $258,245 (weighted average price $48.91). The sale was executed under a Rule 10b5‑1 trading plan.

Key Details

Transaction dates: conversion on 2026-03-12; open‑market sale on 2026-03-13.
Sale price/amount: weighted average $48.91 per share; total proceeds ≈ $258,245. Reported per‑trade prices ranged from $48.48 to $49.32.
Conversion: 100,000 Class B shares converted to Class A shares at $0 cash outlay (Class B convertible one‑for‑one; no expiration).
Holding vehicle/disclaimer: some securities are reported as held by BFI Co., LLC (a vehicle over which Mr. Bendheim exercises voting/dispositive power); Mr. Bendheim disclaims beneficial ownership except to the extent of his pecuniary interest.
Sales mechanism: sales were effected pursuant to a 10b5‑1 plan adopted by BFI on Dec 11, 2025.
Shares owned after transaction: not specified in this Form 4.
Filing timeliness: form filed 2026-03-16 for transactions on 3/12–3/13; no late‑filing flag is indicated in the filing.

Context

The conversion of Class B to Class A is a paperwork/structural change (one‑for‑one conversion) and did not involve cash. The only cash‑generating action reported here was the small open‑market sale of 5,280 shares under a pre‑arranged 10b5‑1 plan, which is typically a routine, pre‑planned disposition rather than an ad‑hoc sale reflecting new information.

Form 4

Period: 2026-03-12

DirectorPresident and CEO10% Owner

Transactions

Conversion
Class A Common Stock
[F1][F2]
2026-03-12+100,000→ 101,480 total(indirect: See)
Sale
Class A Common Stock
[F3][F4][F2]
2026-03-13$48.91/sh−5,280$258,245→ 96,200 total(indirect: See)
Conversion
Class B Common Stock
[F1][F2]
2026-03-12−100,000→ 19,596,034 total(indirect: See)
Exercise: $0.00→ Class A Common Stock (100,000 underlying)

Holdings

Footnotes (5)

[F1]Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date.
[F2]The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of Phibro Animal Health Corporation (the "Issuer"), exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
[F3]The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI on December 11, 2025.
[F4]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.48 to $49.32. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F5]The reported securities are directly held by Jack Bendheim.

1 file